1st Author, year (reference) | Study site | DSMB | Hypothesis | Masking | Comparator drug(s) | Experimental drug(s) |
---|---|---|---|---|---|---|
Luntamo 2010 [39] | Malawi | Yes | Superiority | Single-blinded | Two-dose IPTp-SP | AZ-SP Monthly SP |
Valea 2010 [40] | Burkina Faso | No | Superiority | Not stated | Two-dose IPTp | Three IPTp-SP |
Diakite 2010 [41] | Mali | Yes | Superiority | Open-label | Two-dose IPTp | Three IPTp-SP |
Ndyomugyenyi 2011 [42] | Uganda | Yes | Superiority | Double blinded | IPTp-SPITN + placebo | IPTp-SP + ITN |
Wini 2013 [43] | Solomon Islands | Yes | Superiority | Open-label | IPTp-SP | -CQ prophylaxis |
Denoeud-Ndam 2014 [44] | Benin | Yes | Noninferiority | Open-label | IPTp-MQ,(IPTp-MQ) and CTX (low CD4) | CTX(low CD4)CTX(high CD4) |
González 2014 [45] | Benin, Gabon, Mozambique, and Tanzania | Yes | Superiority | Open-label | IPTp-SP | Two-dose MQ Split-dose MQ |
González 2014 [46] | Kenya, Mozambique, and Tanzania | Yes | Superiority | CTX and Placebo | CTX and (IPTp-MQ) | |
Klement 2014 [47] | Togo | Yes | Noninferiority | Open-label | IPTp-SP | CTX |
Manyando 2014 [48] | Zambia | Yes | Noninferiority | Open-label | IPTp-SP | CTX |
Desai 2015 [49] | Kenya | No | Superiority | Open-label | IPTp-SP | IPTp-DP IST-DP |
Unger 2015 [50] | Papua New Guinea | Yes | Superiority | Single blinded | IPTp-AZCQ | one-dose SP-CQ |
Kakuru 2016 [51] | Uganda | No | Superiority | Double blinded | IPTp-SP, | IPTp-DP IPTp–IPTp-DP |
Kimani 2016 [52] | Benin, Kenya, Malawi, Tanzania, and Uganda | Yes | Superiority | Open-label | IPTp-SP | IPTp-AZCQ |
Natureeba 2017 [53] | Uganda | No | Superiority | Double blinded | TMP-SMX | TMP-SMX + DP |
Divala 2018 [54] | Malawi | Yes | Superiority | Open-label | IPTp-SP | IPTp-CQ CQ prophylaxis |
Akinyotu 2018 [55] | Nigeria | No | Superiority | Single-blind | IPTp-SP | IPTp-MQ |
Kajubi 2019 [56] | Uganda | No | Superiority | Double-blind | IPTpSP | IPTpDP |